In the BioHarmony Drug Report Database

"Preview" Icon

Eribulin

Halaven (eribulin) is a small molecule pharmaceutical. Eribulin was first approved as Halaven on 2010-11-15. It is used to treat breast neoplasms and liposarcoma in the USA. It has been approved in Europe to treat breast neoplasms and liposarcoma. The pharmaceutical is active against tubulin beta chain. Halaven’s patents are valid until 2027-01-08 (FDA).

 

Trade Name

 

Halaven
 

Common Name

 

eribulin
 

ChEMBL ID

 

CHEMBL1683590
 

Indication

 

breast neoplasms, liposarcoma
 

Drug Class

 

Antineoplastics (mitotic inhibitors,tubulin binders

Image (chem structure or protein)

Eribulin structure rendering